ANEB vs. AMRN, KMDA, BNTC, YMAB, AURA, DSGN, UPXI, DMAC, ALT, and IVVD
Should you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Amarin (AMRN), Kamada (KMDA), Benitec Biopharma (BNTC), Y-mAbs Therapeutics (YMAB), Aura Biosciences (AURA), Design Therapeutics (DSGN), Upexi (UPXI), DiaMedica Therapeutics (DMAC), Altimmune (ALT), and Invivyd (IVVD). These companies are all part of the "pharmaceutical products" industry.
Anebulo Pharmaceuticals vs. Its Competitors
Amarin (NASDAQ:AMRN) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Anebulo Pharmaceuticals has a net margin of 0.00% compared to Amarin's net margin of -47.22%. Amarin's return on equity of -21.18% beat Anebulo Pharmaceuticals' return on equity.
Anebulo Pharmaceuticals has lower revenue, but higher earnings than Amarin. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.
Amarin has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.89, suggesting that its stock price is 189% less volatile than the S&P 500.
Amarin currently has a consensus price target of $12.00, suggesting a potential downside of 39.91%. Anebulo Pharmaceuticals has a consensus price target of $5.50, suggesting a potential upside of 102.21%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than Amarin.
In the previous week, Amarin had 14 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 15 mentions for Amarin and 1 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.83 beat Amarin's score of 0.14 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the news media.
22.3% of Amarin shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 3.3% of Amarin shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Anebulo Pharmaceuticals beats Amarin on 9 of the 15 factors compared between the two stocks.
Get Anebulo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anebulo Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ANEB) was last updated on 10/16/2025 by MarketBeat.com Staff
